Inovio Pharmaceuticals Inc (Inovio) develops active DNA immunotherapies and vaccines for the treatment and prevention of cancers and infectious diseases. The company develops drugs based on two distinct proprietary technologies: Cellectra electroporation delivery technology and SynCon DNA plasmid technology. The company’s DNA-based immunotherapies, in combination with its proprietary electroporation delivery technology, are intended to generate immune responses, especially T cells to fight target diseases.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Inovio's R&D efforts focus on the discovery and development of potential new synthetic DNA immune therapies with the objective of producing first-in-class medicines and preventives. The major technologies used by the company include Cellectra electroporation delivery technology and SynCon DNA plasmid technology. The major pipeline products of the company include, INO-4800, INO-4802, INO-4201, VGX-3100, INO-3107, INO-5401, and INO-A002. In FY2022, the company spent US$187.6 million on its R&D activities. The company hold 100 US patents and around 800 issued foreign counterpart patents. It also has number of pending patent applications in the US and foreign countries.